Roche reports FY25 group sales CHF 61.52B vs. CHF 60.5B last year

Reports core EPS CHF 19.46 vs. CHF 18.80 last year. Group sales grew by 7% at constant exchange rates, driven by strong demand for medicines and diagnostic solutions. Sales in the fourth quarter increased by 8%, reflecting the positive momentum. Pharmaceuticals Division sales increased by 9%, with Phesgo, Xolair, Ocrevus, Hemlibra and Vabysmo being the top growth drivers. Diagnostics Division sales grew 2% as demand for pathology and molecular solutions continued to more than offset the impact of healthcare pricing reforms in China. Roche (RHHBY) CEO Thomas Schinecker: “2025 was a strong year for Roche, reflecting our continued focus on operational and R&D excellence. We have significant momentum across our pharmaceutical pipeline: ten potential new medicines advanced into final-stage development, and 12 late-stage clinical studies delivered positive results. We had important breakthroughs in lupus and oestrogen receptor- positive breast cancer, which accounts for approximately 70% of all breast cancer cases, as well as the first positive late-stage clinical results in a new therapy for multiple sclerosis. We are also setting new standards in diagnostics: our next-generation sequencing technology, which will be launched this year, decoded an entire human genome in less than four hours. With our strong financial performance and our continued progress in innovation, we are well positioned for growth.”